April 13, 2020 by Sam Bazzi In a review published by Neurology this week, recommendations were made on how to adjust disease-modifying therapies (DMTs) for people with MS who are infected with SARS-CoV-2 (Brownlee, et al., 2020). In summary, MS patients with minor COVID-19 symptoms should not alter their therapy, as the risk of MS symptoms worsening is generally not worth the potential benefit of altering therapy. If symptoms of COVID-19 are severe, the authors recommend that physicians should consider altering DMTs “with greater immunosuppressant effects. “ It is currently unknown if …
Neurological COVID-19 Case Studies
April 5, 2020 by Sam Bazzi Summary: Currently, there is evidence to suggest that some patients suffering from COVID-19 experience a variety of neurological symptoms, including stroke, delirium, anosmia, epileptic seizures, vomiting, dizziness, and headache. It is unclear how or why these symptoms arise, but some clues exist based on previous coronavirus outbreaks (see Potential Mechanisms). In Wuhan, China, a retrospective study done on 214 confirmed COVID-19 cases assessed neurological symptoms in patients. The cases were classified as severe (88, 41.1%) and non-severe (126, 58.9%). …